Sylvester Comprehensive Cancer Center

E-mail a Friend

Ronan T. Swords, M.D., Ph.D., FRCPI, FRCPath

General Information

Ronan T. Swords, M.D., Ph.D., FRCPI, FRCPath


  • English


  • Hematology/Oncology - Internal Medicine


  • Assistant Professor of Medicine
  • Co-Chair, Clinical Research Services Advisory Committee
  • Co-Leader, Leukemia/Lymphoma/Myeloma Site Disease Group
  • Member, Epigenetics Working Group
  • Member, Molecular Oncology and Experimental Therapeutics (MOET) Program
  • Member, Phase I Clinical Trials Program

Clinical Interests

In my clinic, I primarily see patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). I am particularly interested in novel drug therapies for these diseases. I am also interested in clinical device trials and our recent studies led to the approval of a new and improved technique for bone marrow aspiration and biopsy  (see below). Patients attending the clinic can expect multidisciplinary care relating to diagnosis and management,  where our goal is to provide a  team approach to conventional care treatment, stem cell transplantation and investigational treatment plans. 

OnControl Device – Swords et al


Clinical Research Training Institute (CRTI) ASH scholarship award
FECS/AACR/ASCO "Methods in Cancer Biology Workshop" scholarship award
Oppenheimer Outstanding Researcher of the Year Award
FECS/AACR/ASCO joint “Methods in Clinical Cancer Research” scholarship award


2012 PhD, protein homeostasis in AML
National University of Ireland Galway
2011 FRCPI
Royal College of Physicians of Ireland
2009 Advanced Fellowship, Drug Development
University of Texas Health Science Center San Antonio
2007 FRCPath, Fellowship, Hematology
Royal College of Pathologists London, UK
2002 MRCPI, internal medicine internship and residency
Royal College of Physicians of Ireland
2000 MD (Hons)
National University of Ireland Galway



Dr. Swords is very interested in experimental therapeutics and has been involved in several early phase I/II trials testing new compounds for myeloid blood cancers.

Dr. Swords featuring new Chronic Myeloid Leukemia (CML) Drug
Dr. Swords featuring new Acute Myeloid Leukemia (AML) Drug


Dr. Swords received his undergraduate medical degree with honors from the National University of Ireland Galway, in 2000. After completing his internship and residency in Ireland he became a member of the Royal College of Physicians of Ireland (MRCPI) in 2002 and a fellow of the college (FRCPI) in 2011. Following a 5 year hematology fellowship, he then went on to graduate as  a fellow of the Royal College of Pathologists, London (FRCPath) in 2007 and the following year, he moved to the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center San Antonio (UTSCSA) to pursue his interests in myeloid malignancies and patient oriented research. There, he completed an advanced fellowship in drug development, followed by a PhD in pharmacology and AML biology, under the mentorship and supervision of Dr. Frank Giles, a world leader in early phase drug development.  His research led to the development of a novel first in class inhibitor of NEDD8 protein conjugation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Following completion of his PhD, Dr. Swords moved to the University of Miami in March of 2012, where he is currently leading the development of the leukemia program under the supervision of Dr. Stephen Nimer.


Dr. Swords is a clinical researcher in myeloid blood cancers. In addition to the foundation training outlined, he qualified for a number of scholarship workshops relating to the practical aspects of drug development which included the FECS/AACR/ASCO joint “Methods in Clinical Cancer Research” and “Methods in Cancer Biology Workshop” awards . He also received an ASH mentored research scholarship award  (the Clinical Research Training Institute award),  again in the area of new drug development. Dr. Swords has published over 100 peer reviewed manuscripts and abstracts (see above) in the area of myeloid neoplasia and thematically, his publications focus on translational science and early phase clinical trials for these diseases. Dr. Swords has given oral presentations at local and international meetings including the American Society of Hematology (ASH) and the European Hematology Association (EHA) relating to AML therapeutics. He serves on the editorial board for Leukemia Research Reports and is a manuscript reviewer for a number of high impact factor journals including Blood and Leukemia. He has received funding from private foundations as well as pharma to co

E-mail a Friend